Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas

Table 2

Other antiangiogenesis drugs for recurrent or newly diagnosed malignant gliomas.

Target	Study	Agent	Patients	RR	MPFS	6-PFS	MST	Ref.
Integrin		Cilengitide (500 mg/day)	41  recurrent GBM	5%	7.9 months	10%	6.5 months
	II	(2000 mg/day)	40  recurrent GBM	13%	8.1 months	15%	9.9 months	[73]
Integrin	I/IIa	Cilengitide + RT/TMZ	52  Newly  diagnosed GBM	—	8.0 months	69%	16.1 months	[74]
bFGF	II	Thalidomide	39  recurrent MG	6%	2.5 months	—	7.0 months	[75]
bFGF	II	Thalidomide + carmustine	40  recurrent MG	24%	3.3 months	28%	—	[76]
bFGF	II	Thalidomide + irinotecan	32  recurrent GBM	6%	3.3 months	25%	9.0 months	[77]
bFGF	I	Lenalidomide	24  recurrent GBM	0%	1.8 months	13%	6.0 months	[78]
VEGFR	II	Cediranib (45 mg/day)	31  recurrent GBM	27%	3.9 months	26%	7.6 months	[79]
		Cediranib (30 mg/day)	325  recurrent GBM	—	—	16%	—
VEGFR	III	Cediranib (20 mg/day) + lomustine		—	—	35%	—	[33]
		Lomustine + placebo		—	—	26%	—
VEGFR	II	Adjuvant sorafenib + TMZ	47  newly  diagnosed GBM	13%	6.0 months	50%	12 months	[80]
VEGFR	II	Sunitinib	21  recurrent MG	0%	1.6 months	—	3.8 months	[81]
VEGFR	I	Vatalanib + RT/TMZ	19  newly  diagnosed GBM	13%	7.2 months	—	16.2 months	[82]
VEGFR	II	Pazopanib	35  recurrent GBM	6%	3.0 months	3%	8.8 months	[83]
PDGFR	II	Imatinib	31  recurrent GBM	6%	1.7 months	16%	5.2 months	[84]
PDGFR		Imatinib	120  recurrent GBM	—	1.5 months	7%	5.3 months
	III	Imatinib + hydroxyurea	120  recurrent GBM	—	1.5 months	5%	4.8 months	[85]
PDGFR	R	Dasatinib	14  recurrent GBM	0%	0.9 months	0%	2.6 months	[86]

RR: response rate; MPFS: median progression-free survival; 6-PFS: 6-month progression-free survival; MST: median overall survival time; GBM: glioblastoma multiforme; RT: radiotherapy; TMZ: temozolomide; bFGF: basic fibroblast growth factor; MG: malignant gliomas; VEGFR: vascular endothelial growth factor receptor; PDGFR: platelet-derived growth factor receptor; R: retrospective.